ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0684

Extended Report: Successful Treatment anti-MDA5 Antibody-positive Interstitial Lung Disease with Plasma Exchange Therapy

Yoshiyuki Abe1, Masahiro Kogami2, Makio Kusaoi2, Kurisu Tada3, Ken yamaji4 and Naoto Tamura3, 1Juntendo University School of Medicine, Tokyo, Japan, 2Juntendo University, Tokyo, Japan, 3Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan, 4Juntendo University School of Medicine Internal Medicine and Rheumatology, Tokyo, Japan

Meeting: ACR Convergence 2021

Keywords: dermatomyositis, interstitial lung disease, Mortality, Myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Muscle Biology, Myositis & Myopathies Poster (0683–0722)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: This study was extended report from our previous study that “Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy” (Rheumatology (Oxford) 59(4):767-71, 2020). Anti-melanoma differentiation-associated gene 5 (MDA5) antibodies are a type of myositis-specific autoantibody. Anti-MDA5 antibodies are closely related to interstitial lung disease (ILD). Intensive immunosuppressive therapy with combination calcineurin inhibitor, and intravenous pulse cyclophosphamide was developed, because rapid progressive-ILD (RP-ILD) with anti-MDA5 antibodies is refractory and fatal. Intensive immunosuppressive therapy was shown to improve patient survival and prognosis. However, 20–30% of cases were still fatal, and we reported that the effectiveness of plasma exchange (PE) therapy for refractory RP-ILD. We aimed to reveal the effect of PE on survival in patients with refractory RP-ILD with anti-MDA5 antibodies.

Methods: We added 6 RP-ILD patients who were positive of anti-MDA5 antibodies with PE. Refractory RP-ILD was defined as radiological progression and/or oxygenation exacerbation within 4 weeks after intensive immunosuppressive therapy. Study approval was obtained from the ethical committee of Juntendo University Hospital (approval number 17-274).

Results: The PE group included 6 former patients and 6 new patients such as 1 with newly refractory cases, 3 with relapsed refractory cases, and 2 with newly severe hypoxia cases that P/F ratio was less than 200. A total of 12 patients were included in the PE group. The 1-year survival rate of the PE group was significantly higher than that of the non-PE group (92% and 25%, respectively, P = 0.03). One patient who showed severe hypoxia at the start of treatment was improved from respiratory failure, but he died of candidemia due to vascular catheter infection.

Conclusion: We revealed the higher 1-year survival rate of PE for refractory or severe hypoxia RP-ILD in patients positive for anti-MDA5 antibodies. Physicians may consider that adding PE in refractory or severe hypoxia RP-ILD patients positive for anti-MDA5 antibodies.

Kaplan-Meier curves for survivability comparing the overall PE group and non-PE group.
The result of the log-rank test was P = 0.005. PE: plasma exchange therapy.


Disclosures: Y. Abe, GlaxoSmithKline, 5; M. Kogami, None; M. Kusaoi, None; K. Tada, None; K. yamaji, None; N. Tamura, AbbVie Japan GK, 6, Bristol-Myers Squibb Co. Ltd, 6, Chugai Pharmaceutical Co. Ltd, 6, Eisai Co. Ltd, 6, Eli Lilly Japan K.K, 6, Glaxo Smith Kline K.K., 6, Janssen Pharmaceutical K.K., 6, Mitsubishi-Tanabe Pharma Co., 6, Novartis Pharma K.K, 6.

To cite this abstract in AMA style:

Abe Y, Kogami M, Kusaoi M, Tada K, yamaji K, Tamura N. Extended Report: Successful Treatment anti-MDA5 Antibody-positive Interstitial Lung Disease with Plasma Exchange Therapy [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/extended-report-successful-treatment-anti-mda5-antibody-positive-interstitial-lung-disease-with-plasma-exchange-therapy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/extended-report-successful-treatment-anti-mda5-antibody-positive-interstitial-lung-disease-with-plasma-exchange-therapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology